Back to Press Releases


October 22, 2015
icons for web-brain.png

INSIGHTEC, the leader in MR guided Focused Ultrasound (MRgFUS) therapy announces today that it has submitted a premarket approval application (PMA) to the U.S. Food and Drug Administration (FDA) for its Exablate Neuro treatment of Essential Tremor.

Exablate Neuro uses high intensity focused ultrasound to thermally ablate the target tissue and continuous MRI to visualize the anatomy, plan treatment and monitor treatment outcomes. In the brain, MRgFUS is used to perform a non-invasive thalamotomy through intact skull to relieve tremor in patients with Essential Tremor.


Essential tremor is the most common movement disorder, affecting more than 5 million people in the United States, and millions more worldwide. It is a progressive and debilitating neurological condition that causes a rhythmic trembling of the hands, head, voice, legs or trunk.


Exablate Neuro noninvasive ablation was investigated as a treatment alternative for these patients. The PMA submission was based on a two arm randomized controlled trial comparing patients undergoing ExAblate MRgFUS treatment with patients undergoing a placebo treatment. Patients in the placebo treatment arm were later allowed to undergo an Exablate Neuro treatment. The FDA granted the Expedited Access Pathway designation.


“This is another major achievement, our third clinical indication submitted for FDA approval and the first PMA for Neurosurgery,“ said Dr. Kobi Vortman, CEO and Founder of INSIGHTEC. “This represents our continued commitment to transform MRgFUS from an investigational technology to a standard of care treatment option for neurological patients,” he concluded.


“This is the first transcranial MRgFUS treatment being reviewed for FDA approval. It follows years of development with significant technological breakthroughs,” said Eyal Zadicario INSIGHTEC’s VP R&D and Neuro Program. “We believe that this is only the  starting point in many neurosurgery developments to come our way in the coming future,” he concluded.


Funding for the study has been provided by the Focused Ultrasound Foundation and BIRD (US-Israel Binational Industry R&D) and INSIGHTEC.


Participating medical sites:

University of Virginia, Stanford University Hospital, University of Maryland, Brigham and Women’s Hospital, Swedish Medical Center, Yonsei University College Of Medicine (Korea), Sunnybrook Hospital, Tokyo Women’s Medical University, Tremor Research Group – Core Lab.

Please fill in the following details and we will get in touch with you. (* Required)

agreement Error

Thank You!

Thank you for contacting us! We will get back to you shortly.

Thank You!

This site is brought to you by INSIGHTEC, © 2018 INSIGHTEC Ltd. All rights reserved.

NGSoft logo